Are drug approvals in jeopardy under Trump’s cuts?

Drug approvals face challenges due to funding cuts implemented during the Trump administration. Budget reductions impact the FDA’s ability to review and approve new medications. Delays in drug approvals occur as a result of decreased resources and staffing. This situation raises concerns about access to new treatments for patients. The FDA continues to work within these constraints to ensure safety and efficacy in drug approval processes.

Learn more on this news visit us at: https://greyjournal.net/news/

Hosted on Acast. See acast.com/privacy for more information.